Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Within-Subject Variability of Clexane in Healthy Adults
NCT02081950Phase 1Completed
- Sponsor
- Chemi S.p.A.
- Start
- Mar 2014
- Primary completion
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enoxaparin in venous thromboembolism (VTE), sponsored by Chemi S.p.A. Primary endpoints: Anti-FXa Maximum Plasma Concentration at 36 hours, Anti-FXa Area Under the Curve to Last Timepoint at 36 hours and 4 more. Started Mar 2014; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02081950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081950.